DIA-GNOSIS, s.r.o.

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Type 2 diabetes

Running trials

• Active, not recruiting

  A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

  NCT07219602· Phase 3· NewAmsterdam Pharma· Source